Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Clinical Evaluation of Potential Indicators of Efficacy and Toxicity of...
share announcement

Clinical Evaluation of Potential Indicators of Efficacy and Toxicity of Anticancer Therapies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 2109

Special Issue Editors

Prof. Dr. Beata Kotowicz

E-Mail Website
Guest Editor
Cancer Biomarker and Cytokines Laboratory Unit, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
Interests: oncology; laboratory medicine; tumor markers; protein biomarkers; cancer diagnosis; monitoring response to treatment; predictive and prognostic factors
Prof. Dr. Anita Chudecka-Glaz

E-Mail Website
Co-Guest Editor
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-204 Szczecin, Poland
Interests: gynecologic oncology; diagnosis and treatment of endometrial cancer; ovarian and cervical cancer; molecular changes; tumor markers; prognostic factors; risk factors
Dr. Anna Dańska-Bidzińska

E-Mail Website
Co-Guest Editor
2nd Chair and Department of Obstetrics and Gynecology Warsaw Medical University, Karowa 2, 00-315 Warsaw, Poland
Interests: gynecologic oncology; diagnosis and treatment of malignant tumors sparing fertility; neuroendocrine tumors; molecular markers; prognostic factors

Special Issue Information

Dear Colleagues,

Recent reports related to cancer biology and the development of cancer treatment modalities, including neoadjuvant therapies (targeted therapies based on specific antibodies or immunotherapies), together with their accompanying clinical challenges, point to the need for continued research in this area. As mentioned in the title, potential indicators may include, but are not limited to, characteristic clinical features that are phenotypically associated with cancer, genetic disorders, markers identified using molecular methods, or other analytes determined in patients’ tissues and body fluids. The study of new parameters in the context of evaluating the effectiveness of oncological treatment during therapy is closely related to its toxicity. The early identification of patients who are likely to benefit from treatment with a reduced risk of adverse effects from its use is one of the priorities in modern oncology. This Special Issue will publish original research and review articles related to the evaluation of various indicators that may be useful in the diagnostic and therapeutic processes of malignancies in the future.

We invite you to publish your papers as part of the Special Issue in the journal Cancers. The topics of this issue are related to the search for new parameters with potential clinical value in diagnostic and therapeutic processes for patients with malignant tumors.

With the development of preclinical studies, a clinical evaluation of the identified indicators is needed. Studies based on materials from patients with malignant tumors provide important information about the possibility of assessing the effectiveness and toxicity of modern therapies. The obtained results, once validated, can be used in oncology in sufficiently large groups of patients. Introducing new parameters into clinical practice will increase time and comfort in the lives of patients with malignant tumors.

This Special Issue aims to publish both experimental and theoretical studies that identify potential indicators that are useful for evaluating the efficacy and toxicity of modern anticancer therapies in clinical specimens from patients with malignancies in various locations. Such topics are consistent with the profile of Cancers, especially in the area of clinical oncology.

Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  1. New predictive factors in patients with malignant cancer treated with neoadjuvant therapy;
  2. New predictive markers to monitor the efficacy of immunotherapy in patients with malignancies in various locations;
  3. The identification of markers associated with the toxicity of anticancer therapies in patients with malignant tumors (neuro-, cardio-, and nephrotoxicity).

We look forward to receiving your contributions.

Prof. Dr. Beata Kotowicz
Prof. Dr. Anita Chudecka-Glaz
Dr. Anna Dańska-Bidzińska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • biomarker
  • molecular biomarkers
  • immunotherapy
  • neoadjuvant chemotherapy
  • targeted therapy
  • predictive factor
  • prognostic factor
  • therapy toxicity
  • treatment response biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2292 KiB  
Article
Neurofilaments as Prognostic Biomarkers in the Assessment of the Risk of Advanced Taxane-Induced Neuropathy in Breast Cancer Patients—A Pilot Study
by Agata Makówka, Malgorzata Fuksiewicz, Anna Bałata, Anna Borowiec, Katarzyna Pogoda, Zbigniew Nowecki, Agnieszka Jagiello-Gruszfeld, Beata Janas and Beata Kotowicz
Cancers 2025, 17(6), 988; https://doi.org/10.3390/cancers17060988 - 14 Mar 2025
Viewed by 476
Abstract
Objectives: The aim of the present study was to assess the clinical value of measuring the concentration of neurofilament light chains (NF-Ls) in the diagnosis of taxane-induced neuropathy (CIPN) during neoadjuvant chemotherapy (NAC) in breast cancer patients. Methods: This study included a total [...] Read more.
Objectives: The aim of the present study was to assess the clinical value of measuring the concentration of neurofilament light chains (NF-Ls) in the diagnosis of taxane-induced neuropathy (CIPN) during neoadjuvant chemotherapy (NAC) in breast cancer patients. Methods: This study included a total of 94 patients who qualified for NAC with taxanes. Serum samples were collected before starting NAC, after three and six cycles, and 3–6 months after NAC. The NF-L concentration was determined using the Ella technology. The assessment of CIPN was based on the clinical symptoms included in the EORTC QLQ-CIPN20 scores. Results: The median NF-L concentrations increased during NAT monitoring. After the end of therapy, a significant decrease in NF-L concentrations was observed (p = 0.001, R = 0.37). We established a cut-off point of 29.5 pg/mL to distinguish between the control group and patients with early symptoms of neuropathy (CIPN G1) (p = 0.001; AUC = 0.982). We showed that NF-L concentrations, regardless of the stage of therapy, increased with the severity of neuropathy symptoms (CIPG1 vs. G2 vs. G3) (p = 0.0189, R = 0.33). According to the established cut-off points, serum NF-L concentrations above 196 pg/mL in patients undergoing therapy likely indicate the presence of low-grade neuropathy (p = 0.0076), while values above 218 pg/mL may indicate advanced CIPN (p = 0.0008). Conclusions: In this study, we demonstrated the usefulness of NF-L levels to confirm neuropathy early in the course of treatment, which is important as the questionnaire-based assessment of neuropathy currently used in practice remains subjective. Ultimately, serum NF-L levels are helpful in determining the severity of NAC-induced neuropathy among breast cancer patients. Full article
(This article belongs to the Special Issue Clinical Evaluation of Potential Indicators of Efficacy and Toxicity of Anticancer Therapies)
►▼ Show Figures

Figure 1

10 pages, 925 KiB  
Article
Long-Term Outcomes of 5-Fluorouracil-Related Early-Onset Toxicities: A Retrospective Cohort Study
by Nicolás Tentoni, Ryan Combs, Miriam Hwang, Suzanne Ward, Andrea McCracken, Jennifer Lowe and Scott C. Howard
Cancers 2024, 16(23), 4050; https://doi.org/10.3390/cancers16234050 - 3 Dec 2024
Cited by 1 | Viewed by 1124
Abstract
Objectives: We aimed to determine whether the occurrence of early-onset toxicities due to 5-fluorouracil (5-FU) in treatment-naive patients undergoing their first cycle of FOLFOX/FOLFIRINOX was associated with decreased overall survival, increased risk of treatment cessation, and hospitalization. Methods: This was a retrospective cohort [...] Read more.
Objectives: We aimed to determine whether the occurrence of early-onset toxicities due to 5-fluorouracil (5-FU) in treatment-naive patients undergoing their first cycle of FOLFOX/FOLFIRINOX was associated with decreased overall survival, increased risk of treatment cessation, and hospitalization. Methods: This was a retrospective cohort study using patient information from community oncology practices. Patients who received their first dose of 5-FU from 1 January 2015 through 1 August 2023 were included. The occurrence of an early-onset 5-FU-related toxicity (during 5-FU infusion or up to 96 h after infusion completion) in the first cycle of FOLFOX/FOLFIRINOX was the explanatory variable. The primary endpoint was overall survival (OS); secondary endpoints included early treatment cessation and early hospital admission. Results: In total, 3988 patients were included; the median age was 62.9 years and 57.5% were male. Early-onset toxicities were observed in 19.1%, with vomiting, thrombocytopenia, and diarrhea being most common. Patients with early-onset toxicities had a median OS of 2.5 years [95% CI 2.2 to 2.9] compared with 5.3 years [95% CI 4.7 to 5.8] in patients without early-onset toxicities (p < 0.001). The occurrence of early-onset toxicities was associated with an adjusted hazard ratio of 1.61 [95% CI 1.44 to 1.80] and was also significantly associated with early treatment cessation (odds ratio [OR] 1.53, 95% CI 1.30 to 1.80) and early hospital admission (OR 8.69, 95% CI 3.45 to 24.18). Conclusions: Early-onset toxicities related to 5-FU during the first cycle of FOLFOX/FOLFIRINOX treatment were associated with poor outcomes. Early recognition and prompt intervention are pertinent to improve outcomes in patients receiving fluoropyrimidine chemotherapy. Full article
(This article belongs to the Special Issue Clinical Evaluation of Potential Indicators of Efficacy and Toxicity of Anticancer Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop